Table 3.
Outcomes of COVID‐19 patients receiving steroids
| Low dose | High dose | p value | |
|---|---|---|---|
| Complications (%) | |||
| Acute stroke | 3.2 | 5.4 | 0.057 |
| Acute intracranial bleeding | 1.8 | 2.4 | 0.44 |
| Acute kidney injury | 25.1 | 36.5 | 0.001 |
| Acute renal failure requiring hemodialysis | 5.1 | 7.8 | 0.06 |
| Venous thromboembolism | 4.6 | 10.6 | 0.001 |
| Blood transfusion | 13 | 25.2 | 0.001 |
| Hospital‐acquired infections | 6.1 | 15.2 | 0.001 |
| Candidemia | 1.2 | 3.6 | 0.009 |
| In‐hospital mortality (%) | 18.6 | 40.7 | 0.001 |
| 28‐day mortality (%) | 17.2 | 39.8 | 0.001 |
| LOS in survivors, median (IQR) | 12 (9–18) | 14 (10–23) | 0.001 |
| Time to death, median (IQR) | 15 (11–24) | 18 (12–26) | 0.13 |
| Disposition (%) | 0.034 | ||
| Home | 36.1 | 39.0 | |
| Home with health | 28.8 | 31.4 | |
| SNF/LTAC/Rehab | 31.4 | 24.8 | |
| Others | 3.7 | 4.9 | |
| Readmissions (%) | 18.9 | 15.1 | 0.11 |
| Death during readmission (%) | 26.4 | 30.7 | 0.51 |
Abbreviations: COVID‐19, coronavirus disease 2019; IQR, interquartile range; LOS, length of hospital stay; LTAC, long‐term acute care; SNF, skilled nursing facility.